DOCSLIB.ORG

Vermont Rabies Control Resource Manual 2018

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Vermont Rabies Control Resource Manual 2018 Vermont Rabies Control Resource Manual 2018 Health Surveillance HealthVermont.gov Table of Contents Introduction ............................................................................................................... 3 Section 1: Rabies in Vermont ........................................................................................5 A. Vermont Rabies Control Overview B. Vermont Rabies Epidemiology Section 2: Vermont-Specific Rules and Statutes .......................................................... 13 A. Reportable and Communicable Diseases Rule B. 20 VSA Chapter 193: Domestic Pet or Wolf-Hybrid Control C. Animal Rabies Vaccination Rules Section 3: National Guidelines .................................................................................... 50 A. Compendium of Animal Rabies Prevention and Control, 2016 B. Human Rabies Prevention—United States, 2008 C. Use of a Reduced (4-Dose) Vaccine Schedule for Postexposure Prophylaxis to Prevent Human Rabies, 2010 Section 4: Vermont Recommendations ....................................................................... 111 A. School Animal Policy Guide Section 5: Rabies Exposure Protocols ......................................................................... 116 A. Human Rabies Exposure Management by Animal Type B. Management of Potential Human Exposures to Rabies C. Rabies Exposure Management for Bat-related Incidents D. Management of Potential Pet Exposures to Rabies Section 6: Rabies Testing and Reporting Forms ........................................................... 121 A. Rabies Specimen Lab Testing and Shipping Instructions B. Request for Rabies Examination C. Rabies Postexposure Prophylaxis Report Form D. Town Health Officer Animal Bite Report Form Vermont Rabies Control Resource Manual 2018 Introduction to Rabies Control Resource Manual Introduction Vermont Rabies Control Resource Manual 2018 is a resource guide for veterinarians, wildlife officials, health care and public health professionals, and others to help prevent and control rabies in Vermont. It contains essential information such as: Vermont-specific rules and regulations on animal bite and treatment reporting and rabies vaccination; national guidelines for postexposure treatment, vaccination and animal quarantine; recommendations for schools on developing an animal policy; and forms and instructions for reporting and animal testing. The table below outlines the contents of each of the five sections. Section 1. Rabies in Vermont Vermont Rabies An overview of rabies, procedures for when a human or pet is bitten by a Control Overview potentially rabid animal, instructions for submitting specimens for rabies testing. Vermont Rabies Tables, charts, and a map showing the detection of rabies in Vermont by animal Epidemiology type, town, and year from 2005 to 2017. Section 2. Vermont-Specific Rules and Statutes Reportable and Rules to protect the public though early and prompt reporting of infectious diseases Communicable to the Health Department. From the Code of Vermont Rules [CVR 13-140-007]. Diseases Rule 20 VSA Chapter 193: Vermont statute on licensing and rabies control in domestic pets and wolf-hybrids. Domestic Pet or Wolf- From Vermont Statutes, Title 20: Internal Security and Public Safety, Chapter 193. Hybrid Control Animal Rabies Rules on administration of rabies vaccination to domestic pets, wolf-hybrids and Vaccination Rules livestock. Section 3. National Guidelines Compendium of Animal Published by the National Association of State Public Health Veterinarians, the 2016 Rabies Prevention and report recommends approaches to rabies prevention and control in animals. Control, 2016 Human Rabies Published in the CDC’s Morbidity and Mortality Weekly Report (2008), the report Prevention – United presents guidelines for rabies postexposure and pre-exposure prophylaxis in States, 2008 humans. Use of a Reduced (4- Dose) Vaccine Schedule Published in the CDC’s Morbidity and Mortality Weekly Report (2010), the report for Postexposure summarizes updates to the 2008 guidelines, including a reduced 4-dose rabies Prophylaxis to Prevent vaccine schedule. Human Rabies, 2010 Section 4. Vermont Recommendations School Animal Policy Provides guidance to schools on developing an animal policy to reduce the risk of Guide human exposure to rabies and other diseases from animals. Section 5. Rabies Exposure Protocols Human Rabies Recommendations for rabies postexposure management in humans by animal type Exposure Management (domestic pets, livestock, wild carnivores, rodents, etc.) by Animal Type Management of A flowchart used to determine course of action when a person is exposed to a Potential Human potentially rabid animal. Exposures to Rabies Rabies Exposure A flowchart used to determine human postexposure management for bat-related Management for Bat- incidents. related Incidents Management of A flowchart used to determine course of action when a pet is exposed to a Potential Pet Exposures potentially rabid animal. to Rabies Section 6. Rabies Testing and Reporting Forms Rabies Specimen Lab Instructions for preparing, packaging and shipping rabies specimens to the Vermont Testing and Shipping Department of Health Laboratory. Instructions Request for Rabies After approval from Infectious Disease Epidemiology, submit this form with Examination specimens to the Health Department Laboratory to request rabies testing. Rabies Postexposure For health care professionals, after administering rabies postexposure prophylaxis, Prophylaxis Report submit this form to the Health Department. Form Town Health Officer For health care professionals, veterinarians, and other adults, use this form to Animal Bite Report report an animal bite to the Town Health Officer. Form For questions about this book, please call 802-863-7240 or e-mail [email protected]. Introduction to Vermont Rabies Control Resource Manual 2018 Back to table of contents Section 1. Rabies in Vermont A. Vermont Rabies Control Overview B. Vermont Rabies Epidemiology Vermont Rabies Control Resource Manual 2018 page 5 Rabies Control Overview What’s in this overview? • Rabies disease and vaccination overview. • Procedure when a human or pet is bitten by a potentially infected wild or domestic animal. • Recommendations for capturing a bat if there has been a possibility of exposure. • Instructions for getting pre-approved specimens tested for rabies at the Vermont Department of Health Laboratory. • Contact information for the USDA Vermont Rabies Hotline, Vermont Department of Health Epidemiology Program, Vermont Department of Health Laboratory, and Vermont Fish and Wildlife Game Wardens. Rabies is a fatal viral disease most commonly found in wildlife. In Vermont, rabies is most commonly found in racoons, foxes, bats, skunks and woodchucks, but domestic animal and human infection is possible. All species of mammals are susceptible to rabies infection. Though there has never been a documented human case of rabies in Vermont, between 1992 and 2017, 73 domestic animals tested positive for rabies – 29 cows, 25 cats, 9 horses, 5 dogs, 4 sheep and 1 pig – and hundreds of cases have been identified among wildlife. The Vermont Department of Health is responsible for leading efforts to prevent rabies infections in humans and for the management of animals that may have exposed humans. Included in this role are: 1. Assessing human and domestic animal rabies exposures 2. Coordinating the management of wildlife that may have exposed humans or domestic animals 3. Coordinating the collection and submission of specimens for testing 4. Providing recommendations for pre- and post-exposure prophylaxis. 5. Performing rabies testing on animal specimens. The USDA Vermont Rabies Hotline (1-800-4-RABIES/802-223-8690) offers general rabies and wildlife information to the public. Rabies is primarily transmitted through bites. Rabies is a disease of the central nervous system. Rabid animals may show unusual aggression, extreme depression, or bizarre behavior, but you cannot tell whether an animal has rabies simply by looking at it. Animals are not infectious until the virus is present in their saliva, around the time of illness onset. 108 Cherry Street • PO Box 70 • Burlington, VT 05402 • HealthVermont.gov Rabies is mainly transmitted through bites when teeth penetrate the skin. Rare non-bite exposures can occur if wet infectious saliva or nervous tissue contacts a fresh open wound or mucous membranes of the eyes, nose or mouth. All salivary exposures by raccoons, skunks, foxes, coyotes, and other wild mammalian carnivores must be considered possible exposures to the rabies virus. Any animal not available for testing must be considered as potentially rabid. Indirect contact (petting or handling an animal, contact with blood, urine, feces or skunk spray) is not an exposure. Promptly following the bite of a potentially rabid animal, the wound should be cleansed with soap and running water and irrigated with a virucidal agent such as a povidone-iodine. Tetanus prophylaxis and measures to control bacterial infection may be administered as indicated. The need for rabies postexposure prophylaxis (rPEP) should be assessed with a medical provider and initiated as soon as possible after exposure to wildlife unless the animal has been tested and shown not to be rabid. Initiation of rPEP is reportable to Vermont Department of Health by health care professionals (section 5.5.2 of the "Reportable and Communicable Diseases Rule" [CVR 13-140-007]). It is the responsibility of
Load more

Recommended publications
  • Evaluation of Prophylactic Efficacy of Human Anti-Rabies
    EVALUATION OF PROPHYLACTIC EFFICACY OF HUMAN ANTI-RABIES MONOCLONAL ANTIBODIES IN A MOUSE MODEL by CHAKRAVARTHY CHENNAREDDY (Under the direction of Zhen Fu) ABSTRACT Rabies post exposure prophylaxis (PEP) includes administration of both vaccine and anti-rabies immunoglobulin. Rabies immunoglobulins are expensive and available in limited quantities. There is an inherent variability in quality and specificity between batches of immunoglobulin preparations and possibility of contamination with known or unknown pathogens. To provide a cost-effective and safe replacement for currently used human rabies immunoglobulin (HRIG) human anti-rabies monoclonal antibodies (huMAbs) were developed. The present study evaluated the overall prophylactic efficacy of SO57 and SOJB MAbs individually, in a mouse model when used in combination with rabies vaccine and compared with conventional HRIG. When the protective effect of antibodies was examined in mice challenged with CVS-N2C virus, a dose-dependent survivorship response was observed in animals treated with antibodies and no animal survived in the control group. At the highest dose of antibody given 80% survivorship was recorded for SO57 and SOJB antibodies where as only 50% survived with HRIG. Serum half-lives were found to be approximately 16 days for SO57 (IgG1); 11 days for SOJB (IgG3) and 8 days for HRIG (polyclonal). Furthermore, we investigated the potential interference of antibodies on vaccine mediated- immunity. When compared to the control group which was given only vaccine shots, the groups of animals given both antibody and vaccine developed lower virus neutralizing antibody (VNA) titers. The VNA titers appear to be a function of dose of antibody given and serum half-life of each antibody.
    [Show full text]
  • Rabies Immune Globulin (Human
    Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please send an e-mail to: [email protected] and include 508 Accommodation and the title of the document in the subject line of your e-mail. HIGHLIGHTS OF PRESCRIBING INFORMATION Single-dose vials containing 2 mL or 10 mL ready-to-use solution with a These highlights do not include all the information needed to use potency of 150 IU/mL.(3) ___________________ ____________________ KEDRAB safely and effectively. See full prescribing information for CONTRAINDICATIONS KEDRAB. ® None. (4) KEDRAB Rabies Immune Globulin (Human) solution for wound ----------------------WARNINGS AND PRECAUTIONS----------------------- infiltration and intramuscular injection • Do not give KEDRAB to persons who have completed rabies pre- or post- Initial U.S. Approval: 2017 exposure prophylaxis because it can interfere with the anamnestic response __________________ _________________ to the rabies vaccine. (5.1) RECENT MAJOR CHANGES • Hypersensitivity reactions, including anaphylaxis, may occur with Indications and Usage KEDRAB. IgA deficient patients with antibodies against IgA are at greater Dosage and Administration (2) MM/2021 risk. Have epinephrine available immediately to treat any acute severe __________________ _________________ INDICATIONS AND USAGE hypersensitivity reactions. (5.2). KEDRAB is a human rabies immune globulin (HRIG) indicated for passive, • Interference with live attenuated virus vaccines. (5.5, 7) transient post-exposure prophylaxis of rabies infection to persons of all ages • KEDRAB is made from human plasma, and may carry a risk of when given immediately after contact with a rabid or possibly rabid animal. transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob KEDRAB should be administered concurrently with a full course of rabies disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease vaccine (1).
    [Show full text]
  • WHO Guide for Rabies Pre and Post Exposure Prophylaxis in Humans Updated 2013
    WHO Guide for Rabies Pre and Post Exposure Prophylaxis in Humans Updated 2013 Health Statistics and Informatics General considerations in rabies Post-Exposure Prophylaxis (PEP) • WHO recommends the use of purified rabies vaccines prepared on cell culture or embryonated eggs (referred to as CCEEVs) for PEP; • These vaccines must comply with WHO criteria for potency, innocuity and have been assessed satisfactorily in humans in well-designed field trials; • WHO strongly recommends discontinuation of production and use of nerve-tissue vaccines and their replacement with CCEEVs. Health StatisticsUpdated and 2013 Informatics Top 10 general considerations in rabies PEP 1. Wounds must be immediately washed/flushed for 15 minutes and disinfected; 2. Rabies PEP is an emergency and as a general rule must not be delayed or deferred. Vaccine and in severe exposure immunoglobulin therapy must be instituted as soon as possible. Health StatisticsUpdated and 2013 Informatics Top 10 general considerations in rabies PEP 3. PEP does not have contraindications if purified rabies immunoglobulin and vaccine are used. Pregnancy and infancy are no contraindications to PEP; 4. PEP must be applied using vaccine regimens and routes of administration that have been proven to be safe and effective; 5. If rabies immunoglobulin is not available on first visit its use can be delayed by a maximum of 7 days from date of first vaccine injection. Updated 2013 Health Statistics and Informatics Top 10 general considerations in rabies PEP 6. Initiation of PEP should not await the results of laboratory diagnosis or be delayed by dog observation when rabies is suspected 7. When suspect rabid animal contacts (excluding bats) occur in an area free of carnivore rabies and where there is adequate rabies surveillance, PEP may not be required.
    [Show full text]
  • Dostupnost Antiinfektiv V České Republice
    aktuálně ročník 27 | číslo 5/2017 LÉKY A PRÁVO Dostupnost antiinfektiv v České republice MVDr. Veronika Valdová Arete‑Zoe, LLC Souhrn Valdová V. Dostupnost antiinfektiv v České republice. Remedia 2017; 27: 509–513. na Seznamu nepostradatelných léčiv Světové zdravotnické organizace figuruje 119 antiinfektiv, z nichž v České republice není registrováno 29. Dalších 10 léčiv je registrováno, ale neobchodováno. Dostupnost antibiotik a dalších nezbytných léčiv má přímý dopad na klinickou praxi. Příkladem je aktuali- zovaný postup pro léčbu sepse a septického šoku, který doporučuje deeskalaci a zacílení na identifikovaný patogen ihned po jeho identifikaci z důvodu snížení zátěže pro organismus pacienta. aktualizované léčebné postupy je nutno brát v úvahu při sestavování národních seznamů nepostradatelných léčiv. Z nepostradatelných tuberkulostatik a antivirotik chybějí v ČR některé fixní kombinace určené pro první linii léčby tuberkulózy a HIV/aIDS. Padělky léčivých přípravků a nedoléčené infekce jsou hlavními příčinami vzniku multirezistentních kmenů původce tuberkulózy. Z hyperimunních sér v ČR chybí sérum proti záškrtu. Vakcíny se potýkají s celosvětovým nedostatkem v důsledku délky a náročnosti výroby. Klíčová slova: antiinfektiva – nepostradatelná léčiva – dostupnost léčiv – nedostatek léčiv – tuberkulóza – HIV/aIDS – sepse. Summary Valdova V. Availability of antiinfectives in the Czech Republic. Remedia 2017; 27: 509–513. the World Health Organization (WHO) lists 119 antiinfectives on the list of essential medicines. Of these, 29 are not registered in the Czech Republic, and another 10 are registered but not marketed. availability of antimicrobials and other essential medicines directly affects clinical practice. One such example is the newly revised guidelines for the treatment of sepsis and septic shock, which recommends deescalation of antibiotic treatment and targeting the causative pathogen immediately after its identification to minimize toxicity to the patient’s metabolism.
    [Show full text]
  • The Selection and Use of Essential Medicines
    This report contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization WHO Technical Report Series 933 THE SELECTION AND USE OF ESSENTIAL MEDICINES Report of the WHO Expert Committee, 2005 (including the 14th Model List of Essential Medicines) World Health Organization Geneva 2006 i WHO Library Cataloguing-in-Publication Data WHO Expert Committee on the Selection and Use of Essential Medicines (14th : 2005: Geneva, Switzerland) The selection and use of essential medicines : report of the WHO Expert Committee, 2005 : (including the 14th model list of essential medicines). (WHO technical report series ; 933) 1.Essential drugs — standards 2.Formularies — standards 3.Drug information services — organization and administration 4.Drug utilization 5. Pharmaceutical preparations — classification 6.Guidelines I.Title II.Title: 14th model list of essential medicines III.Series. ISBN 92 4 120933 X (LC/NLM classification: QV 55) ISSN 0512-3054 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publica- tions — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Kedrab. Reliable Coverage for Every Rabies Exposure
    Indicated for post-exposure prophylaxis (PEP) of rabies infection KEDRAB. RELIABLE COVERAGE FOR EVERY RABIES EXPOSURE Eliminate the HRIG Dosing and Administration Guesswork Ready-to-use human rabies immune globulin (HRIG) solution1 May be stored at room temperature not exceeding 25°C (77°F) for up to one month. Use within one month; do not return to refrigeration1 150 IU/mL potency, the standard for nearly 50 years2 No need for dilution with dextrose1 No need for new HRIG protocols or staff trainings 2-mL vial/300 IU 10-mL vial/1500 IU INDICATIONS AND USAGE KEDRABTM (Rabies Immune Globulin [Human]) is a human rabies immunoglobulin (HRIG) indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection, when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine. • Additional doses of KEDRAB should not be administered once vaccine treatment has been initiated, since this may interfere with the immune response to the rabies vaccine. • KEDRAB should not be administered to patients with a history of a complete pre-exposure or post-exposure vaccination regimen and confirmed adequate rabies antibody titer. SELECTED IMPORTANT SAFETY INFORMATION • Patients who can document previous complete rabies pre-exposure prophylaxis or complete post-exposure prophylaxis should only receive a booster rabies vaccine without KEDRAB, because KEDRAB may interfere with the anamnestic response to the vaccine (ACIP). Please see page 6 for full Important Safety Information and full Prescribing Information on pages 7-19. Visit KEDRAB.com or call 1-855-353-7466 to order KEDRAB today.
    [Show full text]
  • Frequently Asked Questions on Rabies © World Health Organization 2013 All Rights Reserved
    Rabies is one of the oldest diseases known to humans, and is a serious public threat in many countries in South-East Asia. There is still no treatment available once a patient develops the symptoms of rabies. These FAQs are an attempt to provide accepted and evidence-based answers to common questions about the disease. If a person is bitten by an animal: Wounds should be washed and flushed immediately with soap and water for 10–15 minutes. If soap is not available, flush with water alone. This is the most effective first-aid treatment against rabies. Wounds should be cleaned thoroughly with 70% alcohol/ethanol or povidone-iodine, if available. As soon as possible, take the person to a health-care facility for further treatment. To download this booklet and other FAQs about infectious diseases, Frequently Asked Questions please visit: http://www.searo.who.int/about/administration_structure/cds/en/ on Rabies index.html World Health House Indraprastha Estate Mahatma Gandhi Marg New Delhi-110002, India SEA-CD-278 SEA-CD-278 FREQUENTLY ASKED QUESTIONS ON RABIES © World Health Organization 2013 All rights reserved. Requests for publications, or for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – can be obtained from Bookshop, World Health Organization, Regional Office for South-East Asia, Indraprastha Estate, Mahatma Gandhi Marg, New Delhi 110 002, India (fax: +91 11 23370197; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • ADULT IMMUNISATION 2Nd Edition
    Malaysian Society of Infectious Diseases and Chemotherapy GUIDELINES FOR ADULT IMMUNISATION 2nd Edition 1 Quick Guide3 19-21 22-26 27-49 50-59 60-64 ≥65 yrs yrs yrs yrs yrs yrs Influenza* 1 dose annually Tetanus, diphtheria, Substitute 1-time dose of Tdap for Td booster; pertussis (Td/Tdap)* then boost with Td every 10 yrs Varicella* 2 doses Human papillomavirus 3 doses (HPV) Female* Human papillomavirus 3 3 (HPV) Male* doses doses Zoster* 1 dose Measles, mumps, 1 or 2 doses rubella (MMR)* Pneumococcal 1 dose conjugate (PCV)* Pneumococcal 1 or 2 doses 1 dose polysaccharide (PPV)* Meningococcal* 1 or more doses Hepatitis A* 2 doses Hepatitis B* 3 doses Haemophilus 1 or 3 doses influenzaetype b (Hib)* For all persons in this category who meet the age requirements and who lack documentation of vaccination or have no evidence of previous infection; zoster vaccine recommended regardless of prior episode of zoster Recommended if some other risk factor is present (eg, on the basis of medical, occupational, lifestyle, or other) No recommendation *Please refer to relevant section for more details 2 Malaysian Society of Infectious Diseases and Chemotherapy GUIDELINES FOR ADULT IMMUNISATION 2nd Edition Supported by an educational grant from 3 Malaysian Society of Infectious Diseases and Chemotherapy ISBN 978-967-13054-0-9 First Edition Published December 2003 Second Edition Published April 2014, Revised October 2016 Copyright © Malaysian Society of Infectious Diseases and Chemotherapy (MSIDC) 2014 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording and/or otherwise, without the prior written permission from the publisher.
    [Show full text]
  • Human Rabies Immune Globulin (HRIG) Administration Considerations—The ART of HRIG
    AUTUMN 2019 • ISSUE #10 YOUR SOURCE FOR RABIES AWARENESS AND EDUCATION Human Rabies Immune Globulin (HRIG) Administration Considerations—The ART of HRIG Quiz 1. How much of the HRIG dose should you 2. If there is remaining volume of HRIG, administer into and around the wound? where should be administered? o As much as possible o Deltoid same side as vaccine o Approximately half o Deltoid opposite side as vaccine If you weren’t entirely certain of the answers, you are not alone! When it comes to HRIG administration, factors such as selection of wound-site dosage and anatomical site for the remaining HRIG can vary according to situations and it is not always straightforward for HCPs working in emergency rooms (ERs). In general, though, as we will discuss in this article, it is recommended that as much HRIG as possible should be administered into and around the wound, and if there is any remaining HRIG it should be administered collaterally to the side of vaccination.1 As you know, rabies is almost always fatal after a patient becomes symptomatic. Appropriate postexposure prophylaxis (PEP) is critical to prevent central nervous system infection and subsequent death. The Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP) recommend that humans who are exposed to the rabies virus should receive PEP care consisting of wound cleansing, infiltration of HRIG, and rabies vaccination.1 CDC guidelines recommend that HRIG be administered at a dose of 20 IU/kg body weight, with the full dose infiltrated into and around the wound(s), if anatomically feasible.
    [Show full text]
  • Rabies Pre and Post-Exposure Prophylaxis in Humans
    WHOWHO GUIDEGUIDE forfor RabiesRabies PrePre andand PostPost--exposureexposure ProphylaxisProphylaxis inin HumansHumans (revised 15 June 2010) – Department of Neglected Tropical Diseases – Neglected Zoonotic Diseases team (revised 15 June 2010) 1 GeneralGeneral considerationsconsiderations inin rabiesrabies PostPost--ExposureExposure ProphylaxisProphylaxis (PEP)(PEP) WHO strongly advocates the use of purified rabies vaccines prepared on cell culture or embryonated eggs for PEP that comply with WHO criteria for potency, innocuity and have been assessed satisfactorily in humans in well-designed field trials; WHO supports the trend to abandon completely the production and use of brain-tissue including suckling mouse brain vaccines. – Department of Neglected Tropical Diseases – Neglected Zoonotic Diseases team (revised 15 June 2010) 2 GeneralGeneral considerationsconsiderations inin rabiesrabies PEPPEP Immediate washing/flushing and disinfection of the wound plus rapid administration of purified immunoglobulin and vaccine according to the modalities described in these guidelines assure prevention of infection in almost all circumstances Rabies PEP – is an emergency and as a general rule should not be delayed or deferred; – does not have contraindications if purified rabies immunoglobulin and vaccine are used; – must be applied using vaccine regimens and routes of administration that have been proven to be safe and effective. – Department of Neglected Tropical Diseases – Neglected Zoonotic Diseases team (revised 15 June 2010) 3 GeneralGeneral
    [Show full text]
  • [Ehdsi V3.0.0-RC1] Ehealth DSI – Master Value Set Catalogue
    MTC eHealth DSI [eHDSI v3.0.0-RC1] eHealth DSI – Master Value Set Catalogue Responsible : Terminologist CEF eHDSI Service Provider PublishDate : Tue Apr 30 16:24:21 CEST 2019 © eHealth DSI Terminologist CEF eHDSI v3.0.0-RC1 Tue Apr 30 16:24:21 CEST 2019 Page 1 of 624 Service Provider MTC Table of Contents eHDSI-AbsentOrUnknownAllergies 4 eHDSI-AbsentOrUnknownDevices 5 eHDSI-AbsentOrUnknownMedication 6 eHDSI-AbsentOrUnknownProblems 7 eHDSI-AbsentOrUnknownProcedures 8 epSOSActiveIngredient 9 epSOSAdministrativeGender 166 epSOSAdverseEventType 167 epSOSAllergenNoDrugs 168 epSOSBloodGroup 173 epSOSBloodPressure 174 epSOSCodeProb 175 epSOSConfidentiality 176 epSOSCountry 177 epSOSDisplayLabel 184 epSOSDocumentCode 187 epSOSDoseForm 188 epSOSHealthcareProfessionalRoles 204 epSOSIllnessesandDisorders 206 © eHealth DSI Terminologist CEF eHDSI v3.0.0-RC1 Tue Apr 30 16:24:21 CEST 2019 Page 2 of 624 Service Provider MTC epSOSLanguage 557 epSOSMedicalDevices 573 epSOSNullFavor 576 epSOSPackage 577 epSOSPersonalRelationship 580 epSOSPregnancyInformation 582 epSOSProcedures 583 epSOSReactionAllergy 587 epSOSResolutionOutcome 589 epSOSRoleClass 590 epSOSRouteofAdministration 591 epSOSSections 594 epSOSSeverity 595 epSOSSocialHistory 596 epSOSStatusCode 597 epSOSSubstitutionCode 598 epSOSTelecomAddress 599 epSOSTimingEvent 600 epSOSUnits 601 epSOSVaccine 622 © eHealth DSI Terminologist CEF eHDSI v3.0.0-RC1 Tue Apr 30 16:24:21 CEST 2019 Page 3 of 624 Service Provider MTC eHDSI-AbsentOrUnknownAllergies eHDSI-AbsentOrUnknownAllergies Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.47
    [Show full text]
  • The Selection and Use of Essential Medicines
    WHO Technical Report Series 920 THE THE SELECTION AND USE OF This report presents the recommendations of the WHO Expert Committee responsible for updating the WHO Model List of SELECTION ESSENTIAL MEDICINES Essential Medicines. The first part contains a progress report on the new procedures for updating the Model List and the development of the WHO Essential Medicines Library. It continues to present a summary of the Committee’s considerations and AND justifications for additions and changes to the Model List, including USE its recommendations. Annexes to the main report include the revised version of the WHO Model List of Essential Medicines OF (the 13th) and a list of all items on the Model List sorted according ESSENTIAL to their 5-level Anatomical Therapeutic Chemical (ATC) classification codes. Report of the WHO Expert Committee, 2003 MEDICINES (including the 13th Model List of Essential Medicines) WHO T echnical Report Series ISBN 9 2412 0920 8 — 920 9 789241 209205 World Health Organization Geneva i The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO’s constitutional func- tions is to provide objective and reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strate- gies and address the most pressing public health concerns of populations around the world. To respond to the needs of Member States at all levels of development, WHO publishes practical manuals, handbooks and training material for specific categories of health workers; internationally applicable guidelines and standards; reviews and analyses of health policies, programmes and research; and state-of- the-art consensus reports that offer technical advice and recommendations for decision-makers.
    [Show full text]